Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

Details

Language :

English

ISSN :

15560864

Volume :

13

Issue :

6

Database :

Complementary Index

Journal :

Journal of Thoracic Oncology

Publication Type :

Academic Journal

Accession number :

129735091

Full Text :

https://doi.org/10.1016/j.jtho.2018.03.013